The Commission for Protection of Competition has instituted ex officio proceedings for investigation of infringement of competition against four pharmaceutical companies, namely Farmix d.o.o., Beohem-3 d.o.o., Makler d.o.o. and Pharmaswiss d.o.o., all from Belgrade. It is reasonably assumed that said undertakings have been involved in collusive bidding in public procurements of medications used for Hemophilia, i.e. have shared the Hemophilia public supply market in the period from 2014 to 2017. The market sharing practices between competitors are considered to be a form of very serious infringement of competition.

Based on the Commission for Protection of Competition’s reasonable assumption of the existence of objective risks of removal or alteration of evidence in the possession of the parties, the authorized officials of the Commission have conducted dawn raids on the business premises of companies subject to the proceedings concerned immediately following the opening of investigations. On the occasion, they have inspected and checked business premises and belongings of the parties, including computers and other e-data storage media. Also, the Commission has examined contracts, financial and other business documentation, as well as business correspondence, all related to the investigation into the existence of competition infringement.

All persons in possession of data, documents or other relevant information which could contribute to the accurate fact-finding in the proceedings concerned are called upon to submit said to the Commission for Protection of Competition, 25/IV Savska St., Belgrade.